These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22096931)

  • 41. Re: The new Canadian Association for the Study of the Liver HCV guidelines.
    Renner EL; Schreiber RA
    Can J Gastroenterol Hepatol; 2015 Apr; 29(3):164. PubMed ID: 25714088
    [No Abstract]   [Full Text] [Related]  

  • 42. Rapid virological response: is it four or eight weeks?
    Milazzo L; Foschi A; Antinori S
    Hepatology; 2012 Mar; 55(3):979; author reply 980-1. PubMed ID: 22161760
    [No Abstract]   [Full Text] [Related]  

  • 43. [Breakthrough in the treatment of chronic hepatitis C virus infections. Direct acting antivirals heals over 90 percent].
    Weiland O
    Lakartidningen; 2014 Nov; 111(51-52):2280-1. PubMed ID: 25423337
    [No Abstract]   [Full Text] [Related]  

  • 44. The protease inhibitor era: an opportunity to improve the quality of care.
    Muir AJ
    Dig Dis Sci; 2011 May; 56(5):1252-4. PubMed ID: 21416243
    [No Abstract]   [Full Text] [Related]  

  • 45. [Hepatitis C at a crossroads].
    Moradpour D; Dorta G
    Rev Med Suisse; 2010 Jan; 6(233):163-4. PubMed ID: 20214186
    [No Abstract]   [Full Text] [Related]  

  • 46. Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C.
    Maratea D; Messori A; Fadda V;
    Dig Liver Dis; 2012 Jan; 44(1):86-7. PubMed ID: 21930446
    [No Abstract]   [Full Text] [Related]  

  • 47. From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials).
    Marcellin F; Fournier I; Carrieri MP; Poizot-Martin I; Cotte L;
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):733-4. PubMed ID: 27111390
    [No Abstract]   [Full Text] [Related]  

  • 48. [Treatment of hepatitis C: decisive therapeutic advances].
    Bailly F; Hartig-Lavie K; Lebossé F; Pagès-Ecochard M; Zoulim F
    Rev Prat; 2015 Feb; 65(2):255-6. PubMed ID: 25939237
    [No Abstract]   [Full Text] [Related]  

  • 49. Hepatitis C: the end of the beginning and possibly the beginning of the end.
    Alter HJ; Liang TJ
    Ann Intern Med; 2012 Feb; 156(4):317-8. PubMed ID: 22351718
    [No Abstract]   [Full Text] [Related]  

  • 50. [Galexos: an advance against hepatitis C].
    Sabourin G
    Perspect Infirm; 2014; 11(4):57. PubMed ID: 25269245
    [No Abstract]   [Full Text] [Related]  

  • 51. [New developed drugs for chronic hepatitis C].
    Inoue K; Takahashi H; Yoshiba S
    Nihon Shokakibyo Gakkai Zasshi; 2011 Jul; 108(7):1187-99. PubMed ID: 21737973
    [No Abstract]   [Full Text] [Related]  

  • 52. Towards eradication of hepatitis C virus from dialysis units.
    Jadoul M; Horsmans Y
    Lancet; 2015 Oct; 386(10003):1514-5. PubMed ID: 26456906
    [No Abstract]   [Full Text] [Related]  

  • 53. Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD.
    Chan HL; Li PK
    Nat Rev Nephrol; 2016 Jan; 12(1):5-6. PubMed ID: 26592193
    [No Abstract]   [Full Text] [Related]  

  • 54. The iron homeostasis network and hepatitis C virus - a new challenge in the era of directly acting antivirals.
    Sikorska K
    Virulence; 2016 Aug; 7(6):620-2. PubMed ID: 27196953
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical development of hepatitis C virus host-targeting agents.
    Zeisel MB; Baumert TF
    Lancet; 2017 Feb; 389(10070):674-675. PubMed ID: 28087068
    [No Abstract]   [Full Text] [Related]  

  • 56. [The paradox of fatty diet on protease inhibitors against C hepatitis].
    Vida Pérez L
    Gastroenterol Hepatol; 2013 Oct; 36(8):549-50. PubMed ID: 23809310
    [No Abstract]   [Full Text] [Related]  

  • 57. [Treatment of chronic hepatitis C with protease inhibitors: dawn of a new era].
    Keeffe EB
    Eksp Klin Gastroenterol; 2010; (11):111-3. PubMed ID: 21485527
    [No Abstract]   [Full Text] [Related]  

  • 58. [New antivirals against hepatitis C virus(protease inhibitors, polymerase inhibitors, and host factor targeting antivirals)].
    Kato N; Muroyama R
    Nihon Rinsho; 2011 May; 69 Suppl 4():275-81. PubMed ID: 22096931
    [No Abstract]   [Full Text] [Related]  

  • 59. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [New times for the treatment of chronic hepatitis C].
    Gerstoft J; Fomsgaard A
    Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.